DCs can license anti-tumor immune responses by processing and cross-presenting exogenous antigens via MHC class I molecules to CD8 T cells, presenting antigens via MHC class II molecules to CD4 T cells, and secreting immune-stimulatory cytokines. Here, CD8A is linked to neoplasm.